Article

October 11, 2012

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

In this video, Aimee Tharaldson, PharmD, discusses some of the current trends in the specialty pharmacy market. In addition, Dr. Tharaldson specifically comments on the oncology pipeline, which currently has the most activity.

In this video, Aimee Tharaldson, PharmD, Senior Clinical Consultant, Emerging Therapeutics at Express Scripts, discusses some of the current trends in the specialty pharmacy market. "Competition is definitely a big trend that we are seeing right now. There's a lot of specialty drugs competing in different specialty therapy classes," says Dr. Tharaldson. In addition, Dr. Tharaldson specifically comments on the oncology pipeline, which currently has the most activity.

This video was taken on Thursday, October 4, 2012, at the Academy of Managed Care Pharmacy's 2012 Educational Conference in Cincinnati, OH.

Related Videos

Shawn Griffin, MD, sitting for a video interview

Christine Funke, MD

John Michael O'Brien, PharmD, MPH

Kathi Henson, MBA, sitting for a video interview

Mike Fazio, Navista, Cardinal Health

Dr Mingyang Song

Fran Gregory, PharmD, MBA, sitting for a video interview

Casey Koch, PharmD, sitting for a video interview

Dr K. Vish Viswanath

Related Content

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

April 29th 2025

New Developments Warrant Rethinking HCC Transplant Criteria

Jared Kaltwasser

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

senior scientist | Image credit: Ohio State University

April 28th 2025

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

April 23rd 2025

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

AJMC Contributor

Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.

Related Content

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

April 29th 2025

New Developments Warrant Rethinking HCC Transplant Criteria

Jared Kaltwasser

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

senior scientist | Image credit: Ohio State University

April 28th 2025

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

April 23rd 2025

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

AJMC Contributor

Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions